[Importance of analogs of LHRH in the treatment of bone metastasis of cancer of the prostate in 1988].
LHRH analogous drugs cause a marked decrease of the testicular secretion, similar to that noted after pulpectomy or estrogen therapy. The experience acquired enables to consider LHRH analogous drugs as alternative in the first intention treatment of the bone metastases prostatic cancer if pulpectomy is refused or if estrogen therapy indicated because of its cardiovascular risks. It is not yet whether the systematic and long-term adjunction of an anti-androgen to LHRH analogous drugs, really increases its efficacy. In the late stage of bone metastases, when the effects of pulpectomy estrogen therapy have ended, LHRH analogous drugs only result in when the tumor process is still hormone-dependent.
Bessoule
O
O
Service de Rhumatologie, CHRU de Rouen, Hôpital de Boisguillaume.
Le Loët
X
X
Deshayes
P
P
D000726:Androgen Antagonists / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone
Intérêt des analogues de la LHRH dans le traitement des métastases osseuses du cancer de la prostate en 1988.